1. Baetz, BE, Spinler, SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28(11):1354-1373.
Google Scholar | Crossref | Medline | ISI2. Eriksson, BI, Smith, H, Yasothan, U, et al. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7(7):557-558.
Google Scholar | Crossref | Medline3. AGENCY EM . Pradaxa EPAR. European Medicines Agency. Pradaxa EPAR 2010. Accessed September 21, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa#authorisation-details-section
Google Scholar4. Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12):1139-1151.
Google Scholar | Crossref | Medline | ISI5. Paikin, JS, Haroun, MJ, Eikelboom, JW. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther. 2011;9(3):279-286.
Google Scholar | Crossref | Medline6. Administration FaD . Drug Approval Package: Xarelto (rivaroxaban). 2011. wwwaccessdatafdagov
Google Scholar7. Administration FaD . Drug Approval Package: Eliquis (apixaban). 2012. wwwaccessdatafdagov
Google Scholar8. Administration FaD . Drug Approval Package: Savaysa (edoxaban). 2015. wwwaccessdatafdagov
Google Scholar9. Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
Google Scholar | Crossref | Medline | ISI10. Wolf, PA, Dawber, TR, Thomas, HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10):973-977.
Google Scholar | Crossref | Medline | ISI11. Stewart, S, Hart, CL, Hole, DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-364.
Google Scholar | Crossref | Medline | ISI12. Hart, RG, Pearce, LA, Aguilar, MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
Google Scholar | Crossref | Medline | ISI13. Ansell, J, Hirsh, J, Hylek, E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). CHEST. 2008;133(6 suppl):160s-198s.
Google Scholar | Crossref | Medline | ISI14. Hankey, GJ, Eikelboom, JW. Dabigatran etexilate. Circulation. 2011;123(13):1436-1450.
Google Scholar | Crossref | Medline | ISI15. Choi, EJ, Lee, IH, Je, NK. Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era. Int J Cardiol. 2016;220:647-652.
Google Scholar | Crossref | Medline16. Lee, SR, Choi, EK, Han, KD, et al. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study. PLoS One. 2017;12(12):e0189495.
Google Scholar | Crossref | Medline17. January, CT, Wann, LS, Calkins, H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132.
Google Scholar | Crossref | Medline18. Lip, GYH, Banerjee, A, Boriani, G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121-1201.
Google Scholar | Crossref | Medline19. Lee, JM, Joung, B, Cha, MJ, et al. Erratum: 2018 KHRS Guidelines for stroke prevention therapy in Korean patients with nonvalvular atrial fibrillation. Korean J Med. 2018;93(3):311-312.
Google Scholar | Crossref20. Brieger, D, Amerena, J, Attia, JR, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Med J Australia. 2018;209(8):356-362.
Google Scholar | Crossref | Medline21. Kirchhof, P, Benussi, S, Kotecha, D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration With EACTS. Revista Española de Cardiología (English Edition). 2017;70(1):50.
Google Scholar | Crossref | Medline22. Loo, SY, Dell’Aniello, S, Huiart, L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Brit J Clin Pharmaco. 2017;83(9):2096-2106.
Google Scholar | Crossref | Medline23. Staerk, L, Fosbøl, EL, Gadsbøll, K, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011-2015 in Denmark. Sci Rep. 2016;6:31477.
Google Scholar | Crossref | Medline24. Zhu, J, Alexander, GC, Nazarian, S, et al. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):907-920.
Google Scholar | Crossref | Medline25. Brownell, KB, Sezer, A, Jain, S, et al. Trends and predictors of NOAC versus warfarin use for stroke prevention in patients with non-valvular atrial fibrillation. J Am Coll Cardiol. 2020;75(11_supplement_1):518-518.
Google Scholar | Crossref26. Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365(10):883-891.
Google Scholar | Crossref | Medline | ISI27. Granger, CB, Alexander, JH, McMurray, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365(11):981-992.
Google Scholar | Crossref | Medline | ISI28. Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2013;369(22):2093-2104.
Google Scholar | Crossref | Medline | ISI29. Steffel, J, Verhamme, P, Potpara, TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393.
Google Scholar | Crossref | Medline30. January, CT, Wann, LS, Calkins, H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151.
Google Scholar | Medline31. Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
Google Scholar | Crossref | Medline | ISI32. Bai, Y, Shi, XB, Ma, CS, et al. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. Am J Cardiol. 2017;120(9):1689-1695.
Google Scholar | Crossref | Medline33. Lee, SR, Choi, EK, Kwon, S, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50(8):2245-2249.
Google Scholar | Crossref | Medline34. Rutherford, O-CW, Jonasson, C, Ghanima, W, et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J—Cardiovascular Pharmacotherapy. 2020;6(2):75-85.
Google Scholar | Crossref | Medline35. Gundlund, A, Staerk, L, Fosbøl, EL, et al. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant? J Intern Med. 2017;282(2):164-174.
Google Scholar | Crossref | Medline36. Schaefer, JK, Sood, SL, Haymart, B, et al. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Adv. 2017;1(26):2536-2540.
Google Scholar | Crossref | Medline37. Balsam, P, Ozieranski, K, Tyminska, A, et al. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study. Kardiol Pol. 2018;76(5):889-898.
Google Scholar | Crossref | Medline38. Kim, S, Kim, M-S, You, S-H, et al. Conducting and reporting a clinical research using Korean Healthcare Claims Database. Korean J Fam Med. 2020;41(3):146-152.
Google Scholar | Crossref | Medline39. Service, NHI . National health insurance system of Korea. 2015. Accessed July 9, 2021. www.kobia.kr/skin/bbs/downloads_e2/download.php?tbl=policy_report&no=401
Google Scholar40. Ho, KH, van Hove, M, Leng, G. Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC Health Serv Res. 2020;20(1):279.
Google Scholar | Crossref | Medline41. Ko, YJ, Kim, S, Park, K, et al. Impact of the health insurance coverage policy on oral anticoagulant prescription among patients with atrial fibrillation in Korea from 2014 to 2016. J Korean Med Sci. 2018;33(23):e163.
Google Scholar | Crossref | Medline42. Yu, HT, Yang, P-S, Hwang, J, et al. Social inequalities of oral anticoagulation after the introduction of non-vitamin K antagonists in patients with atrial fibrillation. Korean Circ J. 2020;50(3):267-277.
Google Scholar | Crossref | Medline43. Diener, HC, Aisenberg, J, Ansell, J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38(12):860-868.
Google Scholar | Medline44. Lee, KH, Joung, B, Lee, S-R, et al. 2018 KHRS expert consensus recommendation for oral anticoagulants choice and appropriate doses: specific situation and high risk patients. Korean J Med. 2018;93(2):110-132.
Google Scholar | Crossref45. Hammersley, D, Signy, M. Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. Ther Adv Chronic Dis. 2017;8(12):165-176.
Google Scholar | SAGE Journals | ISI46. Halvorsen, S, Atar, D, Yang, H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-1872.
Google Scholar | Crossref | Medline | ISI47. Park, J-K, Kim, J, Baek, YS, et al. 2018 KHRS practical guide on the use of non-vitamin K antagonist oral anticoagulants in Korean patients with atrial fibrillation: how to initiate and organize the follow-up. Korean J Med. 2019;94(1):17-39.
Google Scholar | Crossref48. Lip, GYH, Mitchell, SA, Liu, X, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88-94.
Google Scholar | Crossref | Medline49. Ganse, EV, Danchin, N, Mahé, I, et al. Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation. Stroke. 2020;51(7):2066-2075.